Cargando…

Oncogenomic Approaches in Exploring Gain of Function of Mutant p53

Cancer is caused by the spatial and temporal accumulation of alterations in the genome of a given cell. This leads to the deregulation of key signalling pathways that play a pivotal role in the control of cell proliferation and cell fate. The p53 tumor suppressor gene is the most frequent target in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donzelli, Sara, Biagioni, Francesca, Fausti, Francesca, Strano, Sabrina, Fontemaggi, Giulia, Blandino, Giovanni
Formato:	Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers Ltd. 2008
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2679646/ https://www.ncbi.nlm.nih.gov/pubmed/19440517 http://dx.doi.org/10.2174/138920208784340713

Ejemplares similares

microRNAs: short non-coding bullets of gain of function mutant p53 proteins
por: Donzelli, Sara, et al.
Publicado: (2014)

Targeting mutant p53 in cancer: the latest insights
por: Di Agostino, Silvia, et al.
Publicado: (2019)

Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression
por: Valenti, Fabio, et al.
Publicado: (2015)

Gender, mutant p53 and PML: A growing “affaire” in tumor suppression and oncogenesis
por: Di Agostino, Silvia, et al.
Publicado: (2013)

Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers
por: Ferraiuolo, Maria, et al.
Publicado: (2017)

MicroRNAs: short non-coding players in cancer chemoresistance
por: Donzelli, Sara, et al.
Publicado: (2014)

Hippo and rassf1a Pathways: A Growing Affair
por: Fausti, Francesca, et al.
Publicado: (2012)

PML Surfs into HIPPO Tumor Suppressor Pathway
por: Strano, Sabrina, et al.
Publicado: (2013)

ID4: a new player in the cancer arena
por: Dell'Orso, Stefania, et al.
Publicado: (2010)

Mutant p53 exerts its gain of function through activation of the NF-κB pathway
por: Damalas, A, et al.
Publicado: (2005)

Oncogenic Intra-p53 Family Member Interactions in Human Cancers
por: Ferraiuolo, Maria, et al.
Publicado: (2016)

Exploring the OncoGenomic Landscape of cancer
por: Mateo, Lidia, et al.
Publicado: (2018)

Personalized oncogenomics
por: Jones, Steven JM, et al.
Publicado: (2010)

Precision oncogenomics
por: Ferreira-Gonzalez, Andrea, et al.
Publicado: (2019)

Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma
por: Di Agostino, Silvia, et al.
Publicado: (2018)

The era of precision oncogenomics
por: Carpten, John C., et al.
Publicado: (2018)

Identification of post-transcriptional regulatory networks during myeloblast-to-monocyte differentiation transition
por: Fontemaggi, Giulia, et al.
Publicado: (2015)

CircPVT1: a pivotal circular node intersecting Long Non-Coding-PVT1 and c-MYC oncogenic signals
por: Palcau, Alina Catalina, et al.
Publicado: (2022)

A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions
por: Donzelli, Sara, et al.
Publicado: (2022)

The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex
por: Verduci, Lorena, et al.
Publicado: (2017)

Editorial: Human Tumor-Derived p53 Mutants: A Growing Family of Oncoproteins
por: Haupt, Ygal, et al.
Publicado: (2016)

Mitochondrial DNA: the overlooked oncogenome?
por: Gammage, Payam A., et al.
Publicado: (2019)

The Progenetix oncogenomic resource in 2021
por: Huang, Qingyao, et al.
Publicado: (2021)

New therapeutic strategies to treat human cancers expressing mutant p53 proteins
por: Blandino, Giovanni, et al.
Publicado: (2018)

Paracrine Signaling from Breast Cancer Cells Causes Activation of ID4 Expression in Tumor-Associated Macrophages
por: Donzelli, Sara, et al.
Publicado: (2020)

Gain-of-function mutant p53: history and speculation
por: Bargonetti, Jill, et al.
Publicado: (2019)

Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients
por: Hassin, Ori, et al.
Publicado: (2022)

miR-15/107 microRNA Gene Group: Characteristics and Functional Implications in Cancer
por: Turco, Chiara, et al.
Publicado: (2020)

Non-coding RNAs as Putative Biomarkers of Cancer-Associated Cachexia
por: Donzelli, Sara, et al.
Publicado: (2020)

β-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer
por: Tocci, Piera, et al.
Publicado: (2019)

Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53
por: Vikhanskaya, Faina, et al.
Publicado: (2007)

Glioblastoma Multiforme Oncogenomics and Signaling Pathways
por: Kanu, Okezie O., et al.
Publicado: (2009)

Tetracycline Regulated Systems in Functional Oncogenomics
por: Welman, Arkadiusz, et al.
Publicado: (2007)

Oncogenomic disruptions in arsenic-induced carcinogenesis
por: Sage, Adam P., et al.
Publicado: (2017)

A platform for oncogenomic reporting and interpretation
por: Reisle, Caralyn, et al.
Publicado: (2022)

Selective targeting of p53 gain-of-function mutants in cancer
por: Padmanabhan, Achuth
Publicado: (2018)

Gain-of-function mutant p53 in cancer progression and therapy
por: Zhang, Cen, et al.
Publicado: (2020)

Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches
por: Roszkowska, Katarzyna A., et al.
Publicado: (2022)

Oncogenic Gain of Function in Glioblastoma Is Linked to Mutant p53 Amyloid Oligomers
por: Pedrote, Murilo M., et al.
Publicado: (2020)

miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours
por: Biagioni, Francesca, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_jfkelvi01oe9smqnqqkfttoku2